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Rabies is nearly 100% lethal in the absence of treatment, killing an estimated 59,000 people annually. Vac-
cines and biologics are highly efficacious when administered properly. Sixteen rabies-related viruses (lyssa-
viruses) are similarly lethal, but some are divergent enough to evade protection from current vaccines and
biologics, which are based only on the classical rabies virus (RABV). Here we present the development
and characterization of LyssaVax, a vaccine featuring a structurally designed, functional chimeric glycopro-
tein (G) containing immunologically important domains from both RABV G and the highly divergent Mokola
virus (MOKV) G. LyssaVax elicits high titers of antibodies specific to both RABV and MOKV Gs in mice.
Immune sera also neutralize a range of wild-type lyssaviruses across the major phylogroups. LyssaVax-
immunized mice are protected against challenge with recombinant RABV and MOKV. Altogether, LyssaVax
demonstrates the utility of structural modeling in vaccine design and constitutes a broadened lyssavirus vac-
cine candidate.
INTRODUCTION
Emerging infectious diseases are on the rise (Smith et al., 2014).
The recent outbreaks of Ebola virus, Zika virus, and SARS-CoV-2
highlight our lack of preparedness: despite their relation to
known diseases, few therapeutics were available for rapid distri-
bution. Zoonotic diseases are particularly threatening, because
they often move to new hosts opportunistically and can rarely
be eradicated on a global scale (Cutler et al., 2010; Welburn
et al., 2015).
Rabies is a neglected infectious disease that is responsible for
an estimated 59,000 global human deaths annually (Hampson
et al., 2015; World Health Organization, 2017a), roughly the
same number of deaths caused annually by influenza in the
United States (Kochanek et al., 2011). Whereas millions of peo-
ple survive influenza each year, fewer than 30 cases of human
rabies survival have been documented (Fooks et al., 2017;
Mani et al., 2019). The number of human rabies deaths is likely
underestimated, as studies in developing countries with poor
health infrastructure suggest (Fooks et al., 2014; Mallewa
et al., 2007). Rabies virus (RABV)-induced encephalitis is the
most lethal viral infection known to humankind when no interven-
tion is applied prior to symptoms. Less known is that RABV-
related lyssaviruses cause the same zoonotic disease, have
similar mortality rates as RABV, but are far less studied (Banyard
et al., 2014; Evans et al., 2012). The lyssavirus genus is
comprised of 17 single-stranded, negative-sense RNA viruses
divided into at least three phylogroups (RABV being categorized
in phylogroup I) (Markotter and Coertse, 2018). Classical RABV
circulates on all continents but Antarctica; non-RABV lyssavi-
ruses are endemic in Europe, Africa, Asia, and Australia (Fisher
et al., 2018).
Rabies is highly survivable with prompt administration of vac-
cines and antiserum. RABV vaccines are touted as one of the
lowest cost but highest impact tradeoffs among vaccine-pre-
ventable infectious diseases (comparing procurement cost to
Gavi, the Vaccine Alliance, and governments per death averted)
(Gavi, 2018). Critically, disease from other lyssaviruses is not al-
ways prevented by RABV-based vaccines and biologics: protec-
tion against phylogroup II and III viruses is minimal (Weyer et al.,
2008), and lapses in coverage by post-exposure prophylaxis
(PEP) have even been shown within phylogroup I, despite phylo-
genic proximity to RABV (Liu et al., 2013). Despite this, the avail-
able vaccines were developed solely against RABV (Liu et al.,
2013; Nel, 2001). Investment in studying lyssaviruses and devel-
opment of a pan-lyssavirus vaccine is currently lacking but
would have a profound impact if or when a divergent lyssavirus
emerges.
The fraction of disease burden shared by non-RABV lyssavi-
ruses is unknown: the viral encephalitis and resulting symptoms
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from lyssaviruses are indistinguishable from RABV infections,
and current diagnostic reagents based on the highly conserved
nucleoprotein (N) cannot differentiate between lyssaviruses
(von Teichman et al., 1998; World Health Organization, 2018).
Discriminatory diagnostics are rarely available for either human
cases or surveillance in animal populations (Evans et al., 2012;
Mallewa et al., 2007). Definitive evidence of a non-RABV lyssavi-
rus infection can only be made in post-mortem analysis, and the
methods (sequencing the viral genome or probing with species-
specific antibodies) are not yet standardized. Seroprevalence
studies inwildlife suggest lyssaviruses circulate in low but steady
proportions comparedwith RABV (Mélade et al., 2016; Or1owska
et al., 2020; Suu-Ire et al., 2017). A small number of human
deaths caused by six non-RABV lyssaviruses has been
confirmed, but the actual number is likely higher (Evans et al.,
2012).
Sporadic outbreaks of RABV (Feng et al., 2016; Kuzmin et al.,
2012) and the consistent discovery of new lyssaviruses (Aré-
chiga Ceballos et al., 2013; Hu et al., 2018; Nokireki et al.,
2018) challenge our understanding of lyssavirus evolution and
host switching (Fisher et al., 2018). RABV likely originated as a
bat-derived virus, then spread to terrestrial mammal reservoirs,
notably dogs, numerous times (Badrane and Tordo, 2001).
Canine RABV is now responsible for 95% of human RABV fatal-
ities (Hampson et al., 2015; World Health Organization, 2017a).
Lyssaviruses circulate in bats with two notable exceptions where
the reservoirs have not been identified: Ikoma virus (IKOV) (Mar-
ston et al., 2012) and Mokola virus (MOKV) (Coertse et al., 2017;
Sabeta et al., 2007). The possibility of further terrestrial adapta-
tion and consequent increased risk to humans is of concern.
MOKV, a divergent member of phylogroup II, was one of the first
non-RABV lyssaviruses to be discovered (Shope et al., 1970),
and lack of protection from RABV-based vaccines in animals
has been well documented: for example, MOKV has been iso-
lated from rabies-vaccinated domestic cats multiple times (Nel
et al., 2000; Sabeta et al., 2010, 2007; von Teichman et al.,
1998). Although rare cross-reactivity between RABV and
MOKV has been observed, the current RABV vaccine is unlikely
to provide protection against MOKV (De Benedictis et al., 2016;
Hanlon et al., 2005).
The unique attributes of rabies and its epidemiology call for
economic factors to be considered during vaccine development.
Despite its favorable cost-to-impact tradeoff, the current rabies
vaccine is expensive, especially for rural populations in devel-
oping countries where transmission most often occurs. In addi-
tion, the current vaccine’s long history of safety and reliability
sets a high bar for new iterations. Therefore, in crafting a vaccine
with broadened protection, we aimed for a vaccine similar to cur-
rent vaccines in composition and formulation: inactivated virions
of a single strain. The glycoprotein (G) is the sole protein on the
surface of the lyssavirus virions, and serum virus neutralizing an-
tibodies (VNAs) against G are considered the primary correlate of
protection against rabies disease. Our proposed vaccine there-
fore focuses on engineering the G.
Creating chimeric protein antigens is a well-established tech-
nique for modulating immune responses. The move toward
‘‘epitope-based’’ vaccines is an attractive approach in many ef-
forts to make vaccines with increased safety, potency, and
breadth (Bogdanoff et al., 2017; Wei et al., 2010; Xu et al.,
2011; Zhou et al., 2009). Previous attempts by other groups to
create a chimeric G of RABV G and MOKV G, whether swapping
antigenic sites or entire domains, were inconclusive or unsuc-
cessful (Bahloul et al., 1998; Evans et al., 2018a; Jallet et al.,
1999;Mebatsion et al., 1995). Site switching is necessarily based
on the known antigenic sites of RABV G. Five antigenic regions
where VNAs bind were empirically mapped on RABVG, enabling
deep understanding of neutralization mechanisms and the hu-
moral response against RABV (Benmansour et al., 1991; Cai
et al., 2010; Marissen et al., 2005). However, detailed study of
other lyssavirus Gs has not been carried out, so swapping these
short regionsmaymiss other important sites. This is evident from
recent work in which antigenic sites were swapped between the
Gs of RABV and Lagos bat virus (LBV): site II, considered amajor
site on RABV G, appears to also be immunodominant on LBV G,
but the results of other sites are largely inconclusive (Evans et al.,
2018a). Swapping entire domains did not reliably produce infec-
tious particles (Bahloul et al., 1998; Jallet et al., 1999; Mebatsion
et al., 1995), likely because of the imperfect protein engineering
caused by the lack of structural information at the time. Although
transported to the cell surface and incorporated into budding vi-
rions, the chimeras failed to support viral replication, consistent
with the lack of important structural determinants.
The vaccine described here is based on a RABV vaccine strain
and features a structurally designed chimeric lyssavirus glyco-
protein containing domains from both RABV G and the highly
divergent MOKV G. In mice, the inactivated vaccine elicits high
titers of antibodies, which neutralize a panel of lyssaviruses,
and protects against challenge with RABV and a recombinant
MOKV.
RESULTS
Structure-Based Design of Chimeric Lyssavirus
Glycoproteins
In designing a more broadly protective lyssavirus vaccine, we
initially inserted MOKV G into a RABV vector already containing
a native RABV G (BNSP333; Figure S1A). This strategy has been
successfully employed with various foreign viral Gs in the
BNSP333 vector (Abreu-Mota et al., 2018; Johnson et al.,
2016; Kurup et al., 2015). However, the virus containing both
Gs lost expression of MOKV G rapidly, as indicated by immuno-
fluorescence (Figure S1B). Furthermore, MOKV G alone or in
addition to the native RABV G caused the vector to grow signif-
icantly slower (Figure S1C). Therefore, we pursued a more tech-
nical strategy to create a single chimeric G, whichwould serve as
the only glycoprotein supporting viral entry.
To design a chimeric G, we generated structural models of lys-
savirus Gs by threading their amino acid sequences onto the
most closely related structure available at the time, that of the
vesicular stomatitis virus (VSV) pre-fusion G. We used three
structural modeling programs: I-TASSER (Zhang, 2008),
SWISS-MODEL (Waterhouse et al., 2018), and Phyre2 (Kelley
et al., 2015) (Figure 1A). Despite sharing only ~18% sequence
identity, VSV and RABV Gs appear to share conserved structural
features, such as disulfide bonds (Yang et al., 2020), and VSV
has previously been used to model RABV G (Fernando et al.,




2016). In all of the models, we identified three subdomains in the
ectodomain: a ‘‘clip’’ that consists of a small hairpin-shaped re-
gion near the amino (N) terminus (yellow); a ‘‘core’’ that forms a
large region containing a globular portion, beta sheets, and the
putative fusion domain (orange); and a ‘‘flap,’’ the region near
the transmembrane (TM) domain that associates closely with
the clip and that contains the receptor binding domain (red) (Fig-
ures 1A and 1D). The structure of RABV Gwas recently solved at
both low and high pH levels (Yang et al., 2020). Comparison be-
tween the high pH (pre-fusion) structure and our model shows
similar positioning of the clip, core, and flap (Figure S2), vali-
dating the use of structural modeling for designing chimeric
proteins.
The clip, core, and flap subdomains formed the basis for build-
ing Chimeric G 1 and Chimeric G 2, which are comprised of alter-
nating subdomains from RABV G (blue) and MOKV G (red)
(Figures 1B, 1C, 1E, and 1F). We hypothesized that the design
of a functional G protein requires the amino acid sequences of
the clip and the flap to be derived from the same virus to repro-
duce optimal bonding interactions between these two moieties.
Other important features known about the well-studied RABV
G were incorporated in the chimeric G designs. Extensive
studies have mapped the majority of potently neutralizing mono-
clonal antibodies (mAbs) to five antigenic sites on RABV G (Ben-
mansour et al., 1991; Dietzschold et al., 1988; Prehaud et al.,
1988) (Figure 1D). The chimeric Gs share sites I and II from the
same donor G, and sites III, IV, and minor site ‘‘a’’ from the other
donor G, resulting in relatively balanced immunogenicity. The
short, intracellular carboxy (C) terminal of RABV G interacts
with the matrix protein (M) during viral budding and does not
contribute to antigenicity (Wirblich et al., 2008), so it was main-
tained as RABV in both Chimeric G 1 and 2.
An immunofluorescence assay showed the chimeric Gs to
successfully traffic to the cell surface and exhibit the anticipated
antibody staining patterns (Figure S3). Cells transiently express-
ing Chimeric G 1 or 2 were positively stained by polyclonal sera
generated against RABV G or MOKV G, whereas cells express-
ing a wild-type (WT) G were stained only by their cognate sera.
The human anti-RABV G mAb 4C12 binds in the flap region of
RABV G and thus stains only Chimeric G 1.
Chimeric Glycoprotein Is Functional and Supports Viral
Replication
Four vaccines were then constructed in the BNSP RABV vector
lacking its native G in the fourth position (BNSPDG; Figure 2A).
The G gene of interest was inserted into the second position:
the vaccines rRABV and rMOKV contain the codon-optimized
genes of RABV G or MOKV G, respectively, and the vaccines
rChimera1 and rChimera2 contain the respective chimeric Gs 1
and 2 (Figure 2A). Placing of G in the second position of the
genome instead of its native fourth position increases expression
levels because of the transcription gradient exhibited by rhabdo-
viruses (McGettigan et al., 2003). This increase in expression
also contributes attenuation, which, despite proposed adminis-
tration in an inactivated form, renders the vaccine safer to
work with.
Multiple attempts to recover rChimera2 did not yield appre-
ciable titers of infectious virus, suggesting that the chimeric G
did not efficiently support viral spread. By contrast, rChimera1
was successfully recovered, demonstrating the functionality of
this G. An immunofluorescence assay confirmed that only cells
infected with rChimera1, but not with either rRABV or rMOKV,
exhibited dual staining with both anti-RABV G and anti-MOKV
G reagents (Figure 2B). Furthermore, the presence of foci indi-
cates the virus’s ability to spread from cell to cell mediated solely
by the Chimeric G. Purified virions were analyzed by SDS-PAGE,
which shows comparable incorporation of Chimeric G 1 into vi-
rions as compared with the control vaccines (Figure 2C). rChi-
mera1 is henceforth referred to as LyssaVax.
LyssaVax Is Apathogenic by Intramuscular and
Intranasal Routes
Even though rabies vaccines are administered in an inactivated
(killed) form to humans, safety is a necessary priority during pro-
duction when the virus is live and concentrated. We therefore
analyzed live LyssaVax for any pathogenicity, comparing it with
similar vectors containing the wild-type (WT) G protein from





Figure 1. Structure-Based Design of Chimeric Lyssavirus Glyco-
proteins
(A–C) Structural models of lyssavirus glycoprotein (G) ectodomain monomers.
(A) Representative structural model of a lyssavirus G with proposed structural
domains highlighted (clip in yellow, core in orange, flap in red). Structural
model of Chimeric G 1 (B) and Chimeric G 2 (C) clip domains highlighted in
white, and core and flap domains highlighted in blue or red, corresponding to
patterns in (E) and (F).
(D–F) Linear schematics of a representative lyssavirus G monomer (D) and the
RABV G/MOKVG chimeric Gs named Chimeric G 1 (E) and Chimeric G 2 (F). In
(D), proposed structural domains of the ectodomain are noted (clip in yellow,
core in orange, flap in red), as are the antigenic regions as they are known to
exist on the RABV G: site I (residues 224–229), site II (34–42 and 198–200), site
III (330–338), site IV (263–264), and minor site ‘‘a’’ (342–343).
R333E, attenuating mutation at RABV G residue 333; TM, transmembrane
domain. See also Figures S2 and S3.




inoculation routes, intranasal (i.n.) and intramuscular (i.m.), to
assess potential pathogenicity in Swiss Webster mice (Fig-
ure S4). Both male and female mice were used to ensure sex
did not affect pathogenicity. LyssaVax was apathogenic both
i.n., compared with the SPBN strain of RABV (McGettigan
et al., 2001) (Figure S4A), and i.m., compared with the CVS-
N2c strain (Morimoto et al., 1999) (Figure S4B).
LyssaVax Elicits High Titers of Antibodies against Both
RABV and MOKV
To assess immunogenicity, we administered inactivated Lyssa-
Vax to groups of 10 Swiss Webster mice. Inactivated rRABV
and rMOKV were administered individually as control vaccines.
Figure 3A displays the immunization and blood draw schedule
(including challenge, discussed in the next section). Sera were
analyzed by enzyme-linked immunosorbent assay (ELISA)
against RABVG andMOKVG antigens. To avoid cross-reactivity
with other RABV proteins, soluble Gs were produced, stripped,
and purified from a recombinant VSV, which either expressed
RABV G instead of VSV G or which lacked a G gene and was
trans-complemented with MOKV G. mAbs against each protein
were used to validate the antigen: the mouse anti-RABV G mAb
1C5 and themousemAb 1409-7, which cross-reacts withMOKV
G (Dietzschold et al., 1988) (Figure S5).
Sera were tested to assess immunogenicity before immuniza-
tion (day 0), 7 days following each immunization (days 7, 14, and
35) and just prior to challenge (day 56). Individual mouse half-
maximal responses (EC50s) are compared against RABV G
(Figure 3B) andMOKVG (Figure 3C). Dilution curves of group av-
erages are displayed in Figure S5. Sera from mice immunized
with LyssaVax reacted strongly against both RABV and MOKV
G antigens, nearly matching sera from cognate immunizations.
EC50s of RABV G-specific antibodies were not significantly
different between LyssaVax and rRABV immune sera (Figure 3B).
EC50sofMOKVG-specific antibodies fromLyssaVax-immunized
mice were significantly lower than rMOKV only at day 7 (p =
0.0412; Figure 3C). Sera from mock-immunized mice did not se-
roconvert to either antigen (Figure S5). Together, these data sug-
gest that the chimeric G in LyssaVax is highly immunogenic and
broadens the antigenicity of a single lyssavirus glycoprotein.
Interestingly, sera from rMOKV immunemice reacted to RABV
G (red dots/bars in Figure 3B) and sera from rRABV-immune
mice reacted to MOKV G (blue dots/bars in Figure 3C), although
both at significantly lower levels than LyssaVax sera. In both
cases, titers increased over time (compared with mock-immu-
nized sera), suggesting that these antibody responses were spe-
cific and being boosted by each subsequent immunization.
LyssaVax Elicits RABV Neutralizing Antibodies
Sera frommice immunizedwith LyssaVax neutralized RABV strain
CVS-11 at comparable levels with rRABV control immune sera, as
determined by the rapid fluorescent focus inhibition test (RFFIT)
(Figure 4; Table S1). When normalized to a rabies immunoglobulin
standard, serum containing greater than 0.5 international units per
milliliter (IU/mL) VNAs is considered adequate for protection (Bo-
gel, 1978; Keates, 2010). Neutralizing titers in all 10 LyssaVax-
immunized mice reached >4 IU/mL by day 14 post-immunization
(p.i.; after two vaccine inoculations on days 0 and 7). Titers
A
B C
Figure 2. Construction and Recovery of a
Chimeric Lyssavirus G Vaccine
(A) Viral genome schematics. BNSP333 is the parent
vaccine vector based on RABV strain SAD B19. Its
G is located in the native fourth position and con-
tains the attenuating R333E mutation. BNSPDG is
based on BNSP333 but lacks the native G. All of the
following experimental constructs are based on
BNSPDG: rRABV contains a human codon-opti-
mized (c.o.) RABV G with the attenuating mutation
R333E at the second position; rMOKV contains
human c.o. MOKV G at the second position; rChi-
mera1 (LyssaVax) contains Chimeric G 1, with the
attenuating R333Emutation, at the second position;
and rChimera2 contains Chimeric G 2 at the second
position.
(B) Infection immunofluorescence. VERO cells in-
fected with either LyssaVax (left column), rMOKV
(second column), rRABV (third column), or unin-
fected (right column) were fixed and stained with a
DyLight 488-conjugated human anti-RABV G mAb
4C12 (green) and mouse anti-MOKV G sera (red).
Nuclei labeled in blue by DAPI. Scale bars represent
50 mm.
(C) Analysis of purified virions. 3-mg viral particles
denatured and resolved by SDS-PAGE, then total
protein stained with SYPRO Ruby. Viral proteins are
indicated.




continued to climb after the final immunization on day 28, peaking
at an average of 57.2 IU/mL on day 56 p.i. Sera from mice immu-
nizedwith the control vaccine, rRABV, yielded higher titers at each
time point, but differed significantly (p = 0.0342) only on day 35
p.i., when titers peaked, averaging 103.5 IU/mL. None of the
mock-immunized groups exhibited virus neutralization capability,
as determined by assaying pooled sera. These data demonstrate
the potency of the chimeric G vaccine, because VNA titers are
considered the most important correlate of protection (Both
et al., 2012; World Health Organization, 2017b).
rMOKV immune sera did not neutralize CVS-11 above the 4 IU/
mL level of detection initially used in the RFFIT, despite the high
titers of cross-reactive antibodies observed in the RABV G
ELISA. To address the possibility of VNA titers below 4 IU/mL,
we performed a follow-up assay with larger dilutions of sera
from days 28, 56, and 96 p.i., enabling a 0.2 IU/mL level of detec-
tion (Figure S6). At day 28, only two mice exhibited titers above
this new level of detection at 0.6 and 2 IU/mL, respectively. At
day 56, 9/10 sera exhibited low levels of neutralization, with
four mice achieving titers above the 0.5 IU/mL threshold for
protection.
Antibodies Elicited by LyssaVax Neutralize MOKV G
Pseudotypes
Unlike RABV, neither reference assays nor standards have been
established for non-RABV lyssaviruses. Therefore, to assess the
functionality of anti-MOKV G VNAs within the immunized mouse
sera, we tested sera in a pseudotype neutralization assay. VSV
lacking G and expressing NanoLuciferase and EGFP (VSVDG-
NanoLuc-EGFP) was trans-complemented with MOKV G to
create MOKV G pseudotype viruses (MOKV G PTVs; see Fig-
ureS7 for schematic). Cells expressNanoLuc andEGFPwhen in-
fected with these single round infectious particles; thus, neutral-
ization was measured as a reduction in luminescence. To
account for background, we normalized luminescence to day
0 sera. Three time points were tested, each 1 week following a
boost: days 7, 14, and 35 (Figure 5). Similar to the RFFIT, Lyssa-
Vax-immune sera neutralized MOKV G PTVs at low concentra-
tions, nearly as low as the control rMOKV. Of the two time points
for which half-maximal inhibitory concentrations (IC50) could be
calculated, LyssaVax differed from rMOKV significantly only at
day 35 (p = 0.0133) (Figure 5D). Sera from mice immunized with
rRABVdid not neutralize theMOKVGPTVs. Similar to the rMOKV
sera in the RFFIT assay, high titers of cross-reactive sera seen in
the ELISAdid not correlatewith functional VNAby day 35. Pooled
sera from mock-immunized mice showed no neutralization.
LyssaVax Protects against Lethal Challenge of Both
RABV and rMOKV
The vaccinated mice were challenged at 58 days p.i. (see




Figure 3. Humoral Response to LyssaVax
(A) Schematic timeline of immunization (green syringe), sera collection (red
drop), and challenge (orange bolt) through necropsy (NEC).
(B and C) Development of antibodies over time in groups of mice (n = 10 mice
per group, analyzed in triplicate, mean ± SD) immunized three times with either
LyssaVax (purple), rRABV (blue), or rMOKV (red). Graphs compare half-
maximal responses (EC50s) between sera from immune mice probed against
RABV G (B) or MOKV G (C) antigens in ELISA format. Day 0 samples did not
seroconvert, so EC50 valueswere not calculated. Analysis within time points by
Kruskal-Wallis test and Dunn’s multiple comparisons test (*p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001 for adjusted p values; n.s. is not significant).
See also Figure S5.
Figure 4. RABV Neutralizing Titers over Time
Development of RABV neutralizing antibodies over time, averaged from mice
in groups of mice (n = 10 mice per group, analyzed in duplicate, mean ± SD)
immunized on days 0, 7, and 28 with either rRABV (blue), rMOKV (red), or
LyssaVax (purple), or mock immunized (gray). See Figure 3A for full immuni-
zation scheme. Titers were calculated in international units (IU) per milliliter by
comparison with the US standard rabies immune globulin. Level of detection
(LOD) was 4 IU/mL. Two-way ANOVA and Tukey’s multiple comparisons tests
were performed. *p = 0.034, comparing rRABV and LyssaVax. See also Table
S1 and Figure S6.




(LyssaVax, rRABV, rMOKV, and PBS mock) were split into two
subgroups and challenged with 105 focus-forming units (FFUs)
of either live RABV (SPBN strain) or live rMOKV i.n. (Figures 6
and S8). Mock-immunizedmice lost weight andwere euthanized
by day 12 post-challenge (p.c.) for SPBN and day 15 p.c. for
rMOKV. One animal (mouse 1-4) challenged with SPBN survived
and developed RABV neutralizing titers (Table S1). By contrast,
all mice immunized with LyssaVax maintained weight and were
protected against the live virus challenges. Mice immunized
with the control vaccines were also protected against challenge
with their cognate live virus: rRABV immune mice survived chal-
lenge by SPBN, and rMOKV immune mice survived live rMOKV
challenge. Strikingly, some mice survived non-cognate
challenge as well: three rMOKV immune mice survived SPBN
challenge, and all five rRABV immune mice survived rMOKV
challenge, although two mice (3-6 and 3-9) lost weight and
recovered. Survival of these mice with low or negligible titers of
cross-neutralizing antibodies may suggest alternate mecha-
nisms of protection.
Antibodies Elicited by LyssaVax Neutralize Diverse WT
Lyssaviruses
Because LyssaVax is composed of two component lyssavirus
Gs, we sought to test whether sera elicited by LyssaVax cross-
neutralized non-component viruses. We also included the TLR-
Figure 5. MOKV G Pseudotype Neutralizing
Titers
VNA titers against MOKV G pseudotype viruses
(PTVs). PTVs made by trans-complementing VSV-
DG-NanoLuc-EGFP with MOKV G (Figure S7). VNA
titers measured in sera from mice immunized with
either LyssaVax (purple open circle), rRABV (blue
open square), or rMOKV (red open triangle), or mock
immunized with PBS (gray open inverted triangle).
(A–C) Average titers shown over time: day 7 (A), day
14 (B), and day 35 (C) (n = 10 mice per group,
analyzed in triplicate, mean ± SD).
(D) Pseudotype neutralization by the mAb 1409-7.
Luminescence data background subtracted using
paired sera from day 0 and normalized to 100%
infection in no-sera controls.
(E) Serum IC50 data analyzed by the Mann-Whitney
test (*p = 0.0133).
4 agonist glucopyranosyl lipid adjuvant-
stable emulsion (GLA-SE) as an adjuvant
in some groups. GLA-SE has been shown
to increase the magnitude and breadth of
humoral immune responses and is
currently in clinical trials (Coler et al.,
2010; Patton et al., 2015; Sirima et al.,
2017). We immunized four groups of mice
with either rRABV or LyssaVax, with or
without GLA-SE, following the same
schedule in Figure 3A. Sera from day 47
p.i. were tested in a micro-neutralization
assay against a panel of WT lyssaviruses
spanning two phylogroups: RABV, Euro-
pean bat lyssavirus 1 (EBLV1), Irkut virus (IRKV), and Duvenhage
virus (DUVV) from phylogroup I (Figure 7A); and MOKV, Shimoni
bat virus (SHIBV), Lagos bat virus B (LBV-B), and LBV-D from
phylogroup II (Figure 7B).
Among phylogroup I viruses (Figure 7A), all sera from the four
groups neutralized RABV, as expected. Immune sera from
rRABV with or without GLA-SE also cross-neutralized EBLV1,
DUVV, and IRKV, consistent with cross-reactivity within phy-
logroups previously reported. Neutralizing titers from LyssaVax
with or without GLA-SE were significantly lower than those of
rRABV with or without adjuvant. However, including GLA-SE
with LyssaVax raised the average neutralizing titer for all four vi-
ruses tested (significantly so for DUVV and IRKV), as compared
with unadjuvanted LyssaVax. For DUVV, only 3/10 of the unadju-
vanted LyssaVax-immune samples were neutralizing, whereas
9/10 of LyssaVax + GLA-SE samples neutralized.
Among phylogroup II viruses (Figure 7B), sera from LyssaVax,
both with and without adjuvant, neutralized WT viruses at signif-
icantly higher titers than sera from rRABV (with or without adju-
vant). Strikingly, of the phylogroup II viruses, only WT MOKV
was not neutralized by rRABV-immune sera, and only three sam-
ples exhibited neutralizing titers above baseline in the rRABV +
GLA-SE group. However, rRABV with and without GLA-SE
induced neutralizing titers against WT LBV (B), WT LBV (D),
and WT SHIBV.




Overall, LyssaVax stimulates superior titers of VNAs against
the phylogroup II viruses tested but has lost some capability in
stimulating VNAs against non-RABV phylogroup I viruses.
GLA-SE raised the average VNA titer against all viruses tested
when administered with both LyssaVax and rRABV.
DISCUSSION
Chimeric G Vaccine Rationale
There are a variety of ways to broaden a vaccine’s protective
breadth, some of which have been attempted for lyssaviruses.
A straightforward approach is to create multiple vaccine con-
structs, each expressing a separate lyssavirus G (Evans et al.,
2018b), but this strategy would multiply the cost of a vaccine
already deemed too expensive for the regions that need it
most (van de Burgwal et al., 2017). Furthermore, one lyssavirus
G might be immunodominant over others. Some have proposed
lyssavirus vaccines in live vectors (Kgaladi et al., 2017; Weyer
et al., 2008), which, although less expensive and successful in
wildlife RABV vaccination campaigns (Mähl et al., 2014), are un-
likely ever to be approved for use in humans for safety reasons
(Vuta et al., 2016). Another approach is to add multiple Gs to a
single vaccine construct (Kgaladi et al., 2017). Foreign viral Gs
have been successfully added to the RABV genome, and their
Gs expressed to comparable amounts as the native RABV G
(Abreu-Mota et al., 2018; Keshwara et al., 2019; Willet et al.,
2015). However, the stability of multiple lyssavirus Gs has not
been rigorously tested. In our experience, lyssavirus Gs individ-
ually exhibit different growth speeds and expression levels. Our
preliminary data suggest that when combined in a single vector,
the less efficient G confers a disadvantage to the virus and puts
selective pressure on the virus to lose expression of the G
conferring slower growth. We therefore advocate for a single-G
lyssavirus vaccine construct.
Prior to the recent publication of the RABV G crystal structure
(Yang et al., 2020), our protein design effort benefitted the pre-
fusion G structure of the related rhabdovirus, VSV (Roche
et al., 2007). The VSV G structure enabled us to revisit the
chimera strategy (Mebatsion et al., 1995), design an updated
chimeric lyssavirus G, and generate functional virus. Addition-
ally, despite a lack of detailed knowledge about antigenic re-
gions on non-RABV lyssavirus Gs, care was taken to design a
chimeric G in which potential antigenic sites were ‘‘balanced’’
between the two major domains (Figure 1D). Sites II and III are
likely of highest importance, because they share binding sites
with two of the putative RABV cellular receptors, nicotinic acetyl-
choline receptor (nAChR) and the low-affinity neurotrophin re-
ceptor (p75NTR), respectively, (Lafon, 2005). Although site II has
often been considered the most immunogenic based on the
high proportions of G-specific mAbs that bind it (Benmansour
et al., 1991; Dietzschold et al., 1983), many of the mAbs being
developed to replace the immune sera in PEP bind to site I
(Both et al., 2013). The immunogenicity of site IV has been
demonstrated in mice, humans, and dogs (Cai et al., 2010; John-
son et al., 2002; Ni et al., 1995). Antibody responses to RABV
from different species are not thought to vary significantly (Hor-
ton et al., 2014). Altogether, we believe the domain-based
approach to generating chimeric Gs is a superior option.
Glycosylation sites differ between lyssavirus Gs: RABV G has
three predicted N-linked glycosylation sites at residues 37, 247,
and 319 (Shakin-Eshleman et al., 1992); MOKV G shares the
N319 site but has only one other predicted site at N202. Chimeric
G 1 therefore has two predicted sites: N202 and N319. The N319
site is conserved across lyssaviruses and is suggested to be the
minimal site needed for maturation and trafficking through the
endoplasmic reticulum and Golgi apparatus (Badrane and
Tordo, 2001). N37 has been shown not to be efficiently glycosy-
lated and is likely dispensable for proper G folding and function
(Wojczyk et al., 1998). Finally, it has been suggested that the
N202 site in MOKV G is not glycosylated in vivo (Badrane and
Tordo, 2001). Although further study should define the glycosyl-
ation sites of the chimeric G, our data are consistent with the
cited works because we did not observe evidence of glycosyla-
tion affecting the antigenicity of LyssaVax.
Recovery of Viruses with Chimeric Gs
It is unclear why the Chimeric G 2 did not enable viral recovery.
As the single surface protein, the G carries out numerous tasks,
including trimerization, engaging with cellular receptors, and
mediating fusion between membranes, any of which may have
been disturbed by the newly engineered protein. The immunoflu-
orescence of transfected cells (Figure S3) demonstrates that
Chimeric G 2 is successfully produced, trafficked to the cell sur-
face, and exhibits the anticipated antigenicity, suggesting that
functional rather than structural issues hampered recovery.
Regardless, Chimeric G 1 is a preferable choice for a chimeric
G vaccine because it includes the attenuating mutation R333E
within the flap domain contributed by RABV G (Figure 1E). The
R333 residue in RABV G is critical for association with a putative
RABV cellular co-receptor, the low-affinity neurotrophin recep-
tor, p75NTR (Langevin and Tuffereau, 2002). The R333E mutation
alone abrogates pathogenicity by peripheral infection routes in
adult mice (Mebatsion, 2001) and likely contributed to Lyssa-
Vax’s apathogenicity by both routes tested (Figure S4).
Vaccine-Generated Antibody Responses
Wewere interested in the antibody responses generated against
LyssaVax, because antibodies are indicative of a strong vaccine
response. LyssaVax elicited high titers of IgG antibodies against
both MOKVG and RABVG, as seen by ELISA (Figures 3 and S5).
Figure 6. Survival after Challengewith Pathogenic RABV and rMOKV
Overall survival data post-challenge (p.c.) with either live RABV (SPBN) or live
rMOKV (n = 5 mice per immunization group per challenge virus). Survival was
analyzed using the log rank Mantel-Cox test. See Figure S8 for weight loss
curves.




Sera from rRABV and rMOKV immunizations also contained
appreciable titers of antibodies, which bound to the heterolo-
gous antigen (e.g., sera from mouse immunized with rMOKV
binding to RABV G) (Figure 3) by day 14 p.i. However, ELISAs
detect a wide array of antibodies, regardless of function (e.g.,
neutralizing and non-neutralizing). Furthermore, the antigens
used in the ELISA are detergent solubilized, which may expose
epitopes otherwise inaccessible on live, intact virions.
A smaller subset of antibodies function in neutralizing virus,
and high titers of these VNAs are the best-established correlate
of protection against RABV infection (World Health Organization,
2017b). As such, administration of rabies immune globulin (RIG)
is a critical component of current PEP providing short-term pas-
sive immunity in addition to a vaccine course. LyssaVax-immune
mouse sera neutralized both CVS-11 and MOKV G pseudotypes
at nearly the same levels as control immunizations for either
rRABV or rMOKV, respectively (Figures 4 and 5). Although
RABV VNAs from LyssaVax were lower than controls at days
28 and 35 (Figure 4), they were matched by day 56. Furthermore,
LyssaVax titers at day 35 averaged over 60-fold higher than the
0.5 IU/mL threshold for protection, demonstrating the robust
functionality of the VNAs induced by LyssaVax. Sera from rRABV
and rMOKV controls were only marginally cross-neutralizing in
the RFFIT and PTV neutralization assay (Figures 4 and 5), and
only by late time points.
After establishing robust functional antibody responses
against the component viruses, we designed an immunogenicity
study to assess cross-neutralization with additional lyssaviruses.
Anticipating the possibility of lower VNA titers against non-
component viruses, we adjuvanted LyssaVax and the control
vaccine, rRABV, with the Toll-like receptor 4 (TLR4) agonist
GLA-SE (Figure 7). LyssaVax-immune sera neutralized all viruses
tested; of phylogroup I viruses, LyssaVax-induced sera neutral-
ized significantly less strongly than that of the rRABV control vac-
cine and, in the case of DUVV, required GLA-SE to achieve
neutralization in the majority of samples. Of phylogroup II vi-
ruses, VNA titers induced by LyssaVax + GLA-SE were highest,
and in the case of MOKV and LBV D, unadjuvanted LyssaVax
was significantly higher than even rRABV + GLA-SE. Two results
of the micro-neutralization panel were surprising: the relatively
low VNA titers that LyssaVax generated against non-RABV phy-
logroup I viruses and that rRABV, with and without GLA-SE,
induced cross-neutralizing VNAs against LBV-B, LBV-D, and
SHIBV.
Regarding low phylogroup I VNA titers, it is possible that anti-
genic sites located in the core domain, which is contributed by
MOKV G in LyssaVax, are more important for neutralizing non-
RABV phylogroup I viruses. In a study testing anti-RABV mAbs
against a panel of strains and lyssaviruses, none of the five
mAbs bound to EBLV-1 or DUVV (Hanlon et al., 2001), and
VNA titers against EBLV-1 and DUVV were also lowest in a pre-
viously reported RABV G/MOKV G chimeric vaccine (Bahloul
et al., 1998). These data suggest that, to provide comprehensive
coverage across phylogroups I and II, LyssaVax may need com-
ponents from divergent phylogroup I viruses. It has also been
shown that higher concentrations of anti-RABV sera are
Figure 7. Microneutralization Assay with Panel of WT Lyssaviruses
(A and B) Neutralizing antibody 50% endpoint titers in sera from mice 47 days after first immunization with rRABV (blue/white), rRABV with the adjuvant GLA-SE
(blue/gray), LyssaVax (purple/white), or LyssaVax with GLA-SE (purple/gray) (n = 10 mice per group, analyzed in duplicate, mean ± SD). See Figure 3A for im-
munization scheme. Lyssaviruses tested span two phylogroups: (A) RABV, EBLV-1, DUVV, and IRKV; and (B) MOKV, LBV-D, LBV-D, and SHIBV. All titers
normalized to day 0 sera were pooled within groups. Upper limit endpoint: 2,795. Microneutralizations were analyzed using an ordinary one-way ANOVA test with
Tukey’s multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for adjusted p values; n.s. is not significant).




necessary for neutralizing non-RABV phylogroup I viruses (Han-
lon et al., 2005), so the RABV G-specific titers from LyssaVax
may not have been high enough. The ability of GLA-SE to boost
phylogroup I VNA titers when added to LyssaVax supports this.
Although division of the lyssavirus genus into phylogroups is
based on genetic and antigenic clustering, there are many exam-
ples of less discrete patterns of antigenicity. For example, inter-
phylogroup neutralization has been observed in RABV-vaccinated
laboratory workers with exceptionally high titers (De Benedictis
et al., 2016;Hanlonetal., 2005), and thereareat least twoexamples
of anti-RABV GmAbs reported to cross-neutralize MOKV: 1409-7
(Dietzschold et al., 1988) and JA-3.3A5 (Hanlon et al., 2001).
Furthermore, antigenic cartography studies have determined that
only67%ofantigenicdifferences among lyssavirusGsarepredict-
able from the amino acid sequence (Horton et al., 2010).
In the cases where LyssaVax is cross-neutralizing, it is un-
known whether the sera contain individual cross-reactive anti-
bodies or whether discrete populations of antibodies bind to
each antigen; both possibilities likely contribute. This question
can be answered only by isolating and characterizing mAbs, a
goal of future studies. Knowledge of where physiologically
relevant antibodies bind on non-RABV lyssavirus Gs will be
important for detailed study of how LyssaVax elicits protective
antibodies against multiple lyssaviruses.
Protection from Rabies Disease
Based on the high titers of VNAs against the two component vi-
ruses, which contributed to the chimeric G, we anticipated full
protection. LyssaVax indeed protected all mice challenged
with either RABV or rMOKV, with no weight loss or clinical symp-
toms observed. Although lyssaviruses are typically administered
intracranially, the i.n. route was chosen in this study for several
reasons. First, we observed uniform pathogenicity in female
mice during pathogenicity studies (Figure S4). Second, rMOKV
is not pathogenic by the i.m. route (Figure S4), consistent with
WTMOKV studies (Badrane et al., 2001; Percy et al., 1973; Perrin
et al., 1996). Third, the i.n. route has been shown to be an accept-
able alternative to intracranial injection for RABV challenge (La-
fay et al., 1991; Lewis et al., 2013; Rosseels et al., 2011). Finally,
i.n. inoculation poses a lesser risk to laboratory personnel.
Among thecontrol groups,mice immunizedandchallengedwith
homologous vaccines/viruses survived, as expected (Figures S8C
and S8H), whereas some mice survived challenge with heterolo-
gous virus (Figures S8D and S8G). This was surprising because,
despite appreciable titers of antibodies against heterologous Gs
detected in the ELISA (Figure 3), mice immunized with rMOKV
had marginal RABV-neutralizing titers (Figure 4) and rRABV did
not neutralize MOKV G pseudotypes (Figure 6). However, in light
of the cross-neutralization of other phylogroup I viruses that
rMOKV sera exhibited in Figure 7, the survival is less exceptional.
It is notable that two mice immunized with rMOKV lost weight
and were euthanized, and two mice immunized with rRABV lost
weight after rMOKV challenge and recovered (Figure S8). The
atypical challenge model (attenuated strains administered i.n.)
may be responsible; this would be addressed by the WT chal-
lenge experiment. Given that 9/10 mock-immunized mice were
euthanized (Figure S8A) and the 10th mouse indeed survived af-
ter infection, as evidenced by RABV VNAs detected at necropsy
(Table S1, mouse ID 1-4), we are confident that the mice in Fig-
ures S8D and S8G were successfully infected.
The mechanism for developing broadly neutralizing lyssavirus
VNAs has not been studied and raises important questions about
the antigenic relationships between lyssaviruses and how pro-
tection is conferred. There may be additional, uncharacterized
immune mechanisms that contribute to protection in the
absence of neutralizing antibodies. This possibility warrants
further investigation.
Conclusions
We present a lyssavirus vaccine featuring a single chimeric
glycoprotein that was designed based on observations of pre-
dicted lyssavirus G structures. The chimeric G retains antigenic
qualities of component Gs (RABV and MOKV) and cell-infecting
functionality. When administered as an inactivated vaccine
formulation, it stimulates high titers of neutralizing antibodies
against component viral Gs and some additional lyssaviruses.
Finally, LyssaVax was shown to protect against challenge with
RABV and a recombinant MOKV. Development is needed to
improve VNA titer responses against phylogroup I viruses. We
propose that, with further development, this vaccine could be
employed during a lyssavirus outbreak or supplant current rabies
vaccines in areas where non-RABV lyssaviruses are endemic.
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Bogdanoff, W.A., Perez, E.I., López, T., Arias, C.F., and DuBois, R.M. (2017).
Structural Basis for Escape of Human Astrovirus from Antibody Neutralization:
Broad Implications for Rational Vaccine Design. J. Virol. 92, e01546-17.
Bogel, K. (1978). Proposed International Reference Rabies Vaccine (HDC-
Origin) and the potency tests used to test these products. In Joint WHO/
IABS Symposium on the Standardization of Rabies Vaccines for Human Use
Produced in Tissue Culture [Rabies III], W. Hennessen and R.H. Regamey,
eds. (Karger), pp. 267–271.
Both, L., Banyard, A.C., van Dolleweerd, C., Horton, D.L., Ma, J.K.C., and
Fooks, A.R. (2012). Passive immunity in the prevention of rabies. Lancet Infect.
Dis. 12, 397–407.
Both, L., van Dolleweerd, C., Wright, E., Banyard, A.C., Bulmer-Thomas, B.,
Selden, D., Altmann, F., Fooks, A.R., and Ma, J.K.C. (2013). Production, char-
acterization, and antigen specificity of recombinant 62-71-3, a candidate
monoclonal antibody for rabies prophylaxis in humans. FASEB J. 27, 2055–
2065.
Cai, K., Feng, J.N., Wang, Q., Li, T., Shi, J., Hou, X.J., Gao, X., Liu, H., Tu, W.,
Xiao, L., andWang, H. (2010). Fine mapping and interaction analysis of a linear
rabies virus neutralizing epitope. Microbes Infect. 12, 948–955.
Coertse, J., Markotter, W., le Roux, K., Stewart, D., Sabeta, C.T., and Nel, L.H.
(2017). New isolations of the rabies-related Mokola virus from South Africa.
BMC Vet. Res. 13, 37.
Coler, R.N., Baldwin, S.L., Shaverdian, N., Bertholet, S., Reed, S.J., Raman,
V.S., Lu, X., DeVos, J., Hancock, K., Katz, J.M., et al. (2010). A synthetic adju-
vant to enhance and expand immune responses to influenza vaccines. PLoS
ONE 5, e13677.
Cutler, S.J., Fooks, A.R., and van der Poel, W.H.M. (2010). Public health threat
of new, reemerging, and neglected zoonoses in the industrialized world.
Emerg. Infect. Dis. 16, 1–7.
De Benedictis, P., Minola, A., Rota Nodari, E., Aiello, R., Zecchin, B., Salomoni,
A., Foglierini, M., Agatic, G., Vanzetta, F., Lavenir, R., et al. (2016). Develop-
ment of broad-spectrum human monoclonal antibodies for rabies post-expo-
sure prophylaxis. EMBO Mol. Med. 8, 407–421.
Dietzschold, B., Wunner, W.H., Wiktor, T.J., Lopes, A.D., Lafon, M., Smith,
C.L., and Koprowski, H. (1983). Characterization of an antigenic determinant
of the glycoprotein that correlates with pathogenicity of rabies virus. Proc.
Natl. Acad. Sci. USA 80, 70–74.
Dietzschold, B., Rupprecht, C.E., Tollis, M., Lafon, M., Mattei, J., Wiktor, T.J.,
and Koprowski, H. (1988). Antigenic diversity of the glycoprotein and nucleo-
capsid proteins of rabies and rabies-related viruses: implications for epidemi-
ology and control of rabies. Rev. Infect. Dis. 10 (Suppl 4), S785–S798.
Evans, J.S., Horton, D.L., Easton, A.J., Fooks, A.R., and Banyard, A.C. (2012).
Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine? Vaccine
30, 7447–7454.
Evans, J.S., Selden, D., Wu, G., Wright, E., Horton, D.L., Fooks, A.R., and Ban-
yard, A.C. (2018a). Antigenic site changes in the rabies virus glycoprotein dic-
tates functionality and neutralizing capability against divergent lyssaviruses.
J. Gen. Virol. 99, 169–180.
Evans, J.S., Wu, G., Selden, D., Buczkowski, H., Thorne, L., Fooks, A.R., and
Banyard, A.C. (2018b). Utilisation of chimeric lyssaviruses to assess vaccine
protection against highly divergent lyssaviruses. Viruses 10, 130.
Feng, Y., Shi, Y., Yu, M., Xu,W., Gong, W., Tu, Z., Ding, L., He, B., Guo, H., and
Tu, C. (2016). Livestock rabies outbreaks in Shanxi province, China. Arch. Vi-
rol. 161, 2851–2854.
Fernando, B.-G.G., Yersin, C.-T.T., José, C.-B.B., and Paola, Z.-S.S. (2016).
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Rosseels, V., Nazé, F., De Craeye, S., Francart, A., Kalai, M., and VanGucht, S.
(2011). A non-invasive intranasal inoculation technique using isoflurane anes-
thesia to infect the brain of mice with rabies virus. J. Virol. Methods 173,
127–136.
Sabeta, C.T., Markotter, W., Mohale, D.K., Shumba, W., Wandeler, A.I., and
Nel, L.H. (2007). Mokola virus in domestic mammals, South Africa. Emerg.
Infect. Dis. 13, 1371–1373.
Sabeta, C., Blumberg, L.,Miyen, J., Mohale, D., Shumba,W., andWandeler, A.
(2010). Mokola virus involved in a human contact (South Africa). FEMS Immu-
nol. Med. Microbiol. 58, 85–90.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch,
T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an
open-source platform for biological-image analysis. Nat. Methods 9, 676–682.
Shakin-Eshleman, S.H., Remaley, A.T., Eshleman, J.R., Wunner, W.H., and
Spitalnik, S.L. (1992). N-linked glycosylation of rabies virus glycoprotein. Indi-
vidual sequons differ in their glycosylation efficiencies and influence on cell
surface expression. J. Biol. Chem. 267, 10690–10698.
Shope, R.E., Murphy, F.A., Harrison, A.K., Causey, O.R., Kemp, G.E., Simp-
son, D.I.H., and Moore, D.L. (1970). Two African viruses serologically and
morphologically related to rabies virus. J. Virol. 6, 690–692.
Sirima, S.B., Durier, C., Kara, L., Houard, S., Gansane, A., Loulergue, P., Ba-
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matthias
Schnell (Matthias.Schnell@jefferson.edu).
Materials Availability
Upon request, further information, resources, and reagents are available from the authors pending an executed MTA as well as
biosafety approval of the requesting institution(s).
Data and Code Availability
All data are available upon request to the lead contact author. No proprietary software was used in the data analysis.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Swiss Webster mice (Charles River), age 6-10 weeks, were used in this study. All mice used were female except where noted. Mice
used in this study were handled in adherence to the recommendations described in the Guide for the Care and Use of Laboratory
Animals, and work was approved by the Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University
(TJU) under protocols 01886 and 01940. Mice were housed with up to five individuals per cage, under controlled conditions of hu-
midity, temperature, and light (12 h light, 12 h dark cycles). Food and water were available ad libitum. Animal procedures were con-
ducted under 3% isoflurane/O2 gas anesthesia.
The following cell lines and their culture conditions were used in this work: mouse neuroblastoma (NA) cells were grown in RPMI
(Corning) with 5% fetal bovine serum (FBS, Atlanta Biologicals) and 1X Penicillin/Streptomycin (Corning). The other cell lines were
grown in DMEM (Corning) with 5% FBS and 1X Penicillin/Streptomycin: BSR cells (a derivative of the baby hamster kidney cell
line BHK-21), the African green monkey cell line VERO, and the human lung cell line BEAS-2b. Cells were kept at 37C and 5%
CO2 during non-infectious growth and 34
C with 5% CO2 during infectious growth. Infected cell cultures were cultured in OptiPRO
SFM (Life Technologies) unless otherwise noted.
METHOD DETAILS
Structural modeling and chimeric glycoprotein design
To generate structural models of RABV and MOKV G, their amino acid sequences were threaded onto the pre-fusion structure of
vesicular stomatitis virus (VSV) G (Roche et al., 2007). Three different modeling programs were used to increase the likelihood of pro-
ducing an accurate model: I-TASSER (Zhang, 2008), SWISS-MODEL (Waterhouse et al., 2018), and Phyre2 (Kelley et al., 2015). After
analysis and delineation of the clip, core, and flap regions of the glycoproteins, the proposed chimeric Gwere also threaded onto VSV
G to confirm the placement of the ectodomain regions.
cDNA construction of vaccine vectors
To make the rRABV vector, we inserted a human codon-optimized RABV G (SAD B19 strain with R333E mutation, synthesized by
Genscript USA) into the BNSPDG vector (Blaney et al., 2011) using the BsiWI and NheI restriction sites. Human codon optimization
was selected in anticipation of downstream vaccine production in primate cells. To make the BNSP333-coMOKVG vector, we in-
serted MOKV G (MOKV.NIG68-RV4 strain (Wright et al., 2010), GenBank accession number HM623780, provided by Gene Tan)
into the BNSP333 vector using the InFusion cloning kit (Clontech) and oligos CO-041 and CO-042. To make the rMOKV vector,
we inserted the human codon-optimized MOKV G sequence into the BNSPDG vector using the NotI and NheI restriction sites,
the NotI site having been cloned into the vector previously. To make the chimeric glycoproteins 1 and 2, fragments of codon opti-
mized RABV G and MOKV G were first amplified by PCR using the primers listed in the table below and cloned into a pCAGGS
expression vector via InFusion cloning (Clontech). Three fragments were combined to make Chimeric G 1 (amplified using oligos
CO-062 through CO-067) and four fragments were combined to make Chimeric G 2 (amplified using oligos CO-067 through CO-
074). The chimeric Gs were then cloned into the BNSPDG vector using the NotI and NheI restriction sites to create rChimera1 (later
termed LyssaVax) and rChimera2. The correct sequences of all four plasmids were confirmed by Sanger sequencing.
Recovery of recombinant vectors
Recombinant RABV were recovered as described previously (Abreu-Mota et al., 2018; Kurup et al., 2015; Papaneri et al., 2013).
Briefly, X-tremeGENE 9 transfection reagent (Millipore Sigma) in Opti-MEM reduced serum medium (Life Technologies) was used
to co-transfect the respective full-length viral cDNA clones along with the plasmids encoding RABV N, P, and L and the T7 RNA po-
lymerase into BSR cells in T25 flasks. We harvested the supernatants of transfected cells after 7 days and analyzed the supernatants
for the presence of infectious virus by infecting fresh BSR cell cultures and immunostaining with FITC-conjugated anti-RABV NmAb
(Fujirebio).




To confirm the glycoprotein sequence in the recovered viruses, the viruses were sequenced by the following method: BSR cells
were infected at anMOI of 1 then incubated for 2 days. Media was removed and the PureLink RNAMini Kit (Ambion) was used to lyse
the cells and extract RNA. Using the SuperScript II Reverse Transcriptase (Invitrogen), sections of the viral genomes containing G
were amplified out of the total RNA (primers RP951 and RP952). RT-PCR products were run on an 1% agarose gel and bands
were excised and analyzed by Sanger sequencing using the same primers.
Immunofluorescence
To analyze broadened reactivity of the chimeric glycoproteins, VERO cells grown on 15 mm coverslips (Fisherbrand) were trans-
fected with pCAGGS vectors containing either RABV G, MOKV G, Chimeric G 1 or Chimeric G 2 using XtremeGene 9. Two days
post-transfection, cells were fixed with 4% paraformaldehyde (PFA), blocked with PBS containing 5% FBS, and stained with either
the human anti-RABV GmAb 4C12 conjugated to DyLight 488, mouse anti-MOKV G sera (from G. Tan), or mouse anti-RABV G sera
(generated against BNSP333), each at 1:400 dilution and incubated for 2 h at RT. Coverslips were washed with PBS and samples
stained with mouse sera were then stained with Cy3-conjugated goat anti-mouse IgG secondary at 1:200. After a 2 h incubation
at RT, coverslips were washed and mounted onto glass slides with Vectashield Hard Set containing DAPI (Vector Laboratories). Im-
ages of slides were analyzed in ProgRes (Jenoptic) and Fiji software (Schindelin et al., 2012).
Immunofluorescence assays on infected cells were carried out in a similar manner, with the following difference: VERO cells were
infected at MOI 0.01 with live virus (rRABV, rMOKV or LyssaVax in Figure 2; rRABV, rMOKV, BNSP333-MOKVG or BNSP333-RABVG
in Figure S1) then fixed with 4% PFA 2 days post-transfection.
Viral growth curve
Related to Figure S1. BSR cells were seeded in 6-well cell culture plates and incubated until 70% confluent. Cells were then infected
at aMOI of 0.01 for 3 hours, washed 2xwith PBS, and replenishedwithOptiPROmedia (GIBCO). Samples of eachwell were collected
every 24 h, stored at 4C, then titered in triplicate.
Purification and inactivation of the virus particles
Large volumes of rRABV- and LyssaVax-containing supernatants were concentrated in a stirred 300 mL ultrafiltration cell (Millipore)
and then purified over a 20% sucrose cushion in an SW32 Ti rotor (Beckman, Inc.) at 25,000 rpm for 1.5 h ay 4C. rMOKVwas purified
similarly but without prior concentration in ultrafiltration cells. Virion pellets were resuspended in phosphate-buffered saline (PBS),
and protein concentrations were determined using a bicinchoninic acid (BCA) assay kit (Pierce). The virus particles were inactivated
with 50 mL per mg of particles of a 1:100 dilution of b-propiolactone (BPL) in cold water. The absence of infectivity was verified by
inoculating BSR cells with 10 mg of BPL-inactivated viruses. After 4 days of incubation at 34C, the cells were subcultured and
500 mL of supernatant was passaged on fresh BSR cells. Cultures were split 3 times, every 3 days. After the final growth period, cells
were fixed and stained with a FITC-conjugated anti-RABV N mAb to confirm the absence of live virus.
Protein gel
To examine their purity, inactivated virus particles were diluted 1:1 in urea buffer (200 mM Tris-HCl [pH 6.8], 8 M urea, 5% sodium
dodecyl sulfate (SDS), 0.1 mM ethylenediaminetetraacetic acid [pH 8], 0.03% bromophenol blue, and 0.5 M dithiothreitol) and de-
natured at 95C for 5 m. Three micrograms of protein were resolved on a 10% SDS–polyacrylamide gel and stained with SYPRO
Ruby Protein Gel Stain (Invitrogen) according to the manufacturer’s specifications. The gel was then exposed under UV light for
430 ms.
Pathogenicity experiments
Related to Figure S4. Four groups of Swiss Webster mice (Charles River, 5 male and 5 female per group, age 6 to 10 weeks) were
intranasally (i.n.) infected with 105 focus-forming units (FFU) of live virus diluted in 20 mL phosphate-buffered saline (PBS). The mice
were weighed and monitored daily until day 21 post-infection and further monitored until day 30. Mice exhibiting signs of disease or
that lost greater than 25% weight were euthanized. To assess a peripheral route of infection, 4 groups of Swiss Webster mice were
intramuscularly (i.m.) infected with 105 FFU of live virus diluted in 100 mL PBS, distributed equally to muscle of both hind limbs. The
mice were weighed and monitored daily until day 21 post-infection and further monitored until day 28. Mice exhibiting signs of dis-
ease or that lost greater than 25% weight were euthanized. Survival was analyzed using the log-rank Mantel-Cox test in GraphPad
Prism.
Immunization and challenge
Swiss Webster mice (Charles River) were used in this study: groups of female mice, age 6 to 10 weeks, were immunized i.m. with
10 mg BPL-inactivated virus diluted in 100 mL phosphate-buffered saline (PBS) and distributed equally to muscle of both hind limbs.
In groups which received glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE, IDRI), 20 mL of 0.25 mg/ml adjuvant were included
in the 100 mL total per mouse. Mice were immunized on days 0, 7, and 28. Blood was drawn (100 mL via the retro-orbital route) weekly
and centrifuged at 10,000 rpm for 10m for serum collection. Serumwas analyzed from individual mice (unless noted). One set of mice
(Figures 3, 4, 5, and 6) was challenged on day 58 post-immunization (p.i.) with either SPNB or rMOKV. 105 FFU of live virus were




diluted in 20 mL PBS was administered i.n. The mice were weighed and monitored daily until day 21 post-infection and further moni-
tored until day 37.Mice exhibiting signs of disease or that lost greater than 25%weight were euthanized. Survival was analyzed using
the log-rank Mantel-Cox test in GraphPad Prism. The other set of mice (Figure 7) was terminally bled via heart puncture on day 47 p.i.
and euthanized.
Production of soluble RABV and MOKV G
To produce soluble RABV G, BEAS-2b cells were inoculated with VSVDG-GFP-RABVG at MOI 0.01. Three days post-infection, su-
pernatant was collected, filtered through a 0.45 mm filter and concentrated by tangential flow filtration. Concentrated virus was pu-
rified over 20% sucrose cushion in a SW 32 Ti rotor (Beckman) at 25,000 rpm for 2 h. Pellets were resuspended in TEN buffer with 5%
sucrose. To solubilize the glycoprotein, octyglucopyranoside (OGP, Fisher) was added to 2% final concentration and solution was
incubated at room temperature with constant mixing for 30 m. The suspension was spun at max speed in a benchtop centrifuge for
3m to pellet debris. Pellets were treated with OGP in the samemanner 2more times. Pooled supernatants from all 3 extractions were
spun in a SW 55 Ti rotor (Beckman) at 45,000 rpm for 1.5 h. Supernatant containing soluble G was analyzed for protein concentration
by BCA (Pierce), and for purity by SDS-PAGE and western blot.
To produce soluble MOKV G, BEAS-2b cells were transfected with pCAGGS-coMOKVG using the XtremeGene 9 transfection re-
agent (Millipore-Sigma). Two days post-transfection, cells were infected with MOKV G PTVS (described below), and 2 days post-
infection, supernatant containing MOKVG pseudotyped VSV was collected. MOKV G was solubilized from the pseudotype virions
in the same manner as RABV G.
ELISA
To assess vaccine immunogenicity, mouse sera were analyzed by enzyme-linked immunosorbent assay (ELISA), probing for reac-
tivity against either soluble RABV G or MOKV G (production described above). Mouse sera from days 0, 7, 14, 35, and 56 were
analyzed individually in triplicate, except mock infected sera which was pooled. Immulon 96-well plates (Nunc) were coated with sol-
uble G diluted in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3 [pH 9.5]). For RABV G, 50 ng in 100 mL buffer was used per well
and for MOKV G, 25 ng in 50 mL per well. Plates were incubated overnight at 4C. Plates were then washed 3 times with 300 mL per
well of PBS containing 0.05% Tween 20 (PBST), then blocked with 5% milk in PBST (250 mL per well) for 2 h at RT, shaking. Plates
werewashed again, then coatedwith primary buffer (PBSwith 0.5%bovine serum albumen), either 100 mL per well (RABVGplates) or
50 mL per well (MOKV G plates). Serum was diluted 3-fold down the plate in triplicate, starting at either 1:100 or 1:300, then plates
were incubated overnight at 4C. Plates were then washed 3 times and coated with PBST containing HRP-conjugated Goat anti-
mouse IgG (H+L) at 1:10,000. After incubation for 2 h at RT, plates were washed and 200 mL of o-phenylenediamine dihydrochloride
(OPD) substrate (Sigma) was added to each well. After a 15 m incubation, the reaction was stopped by the addition of 50 mL 3M
H2SO4 per well. Optical density was determined at 490 nm (OD490). Individual mouse data were analyzed in GraphPad Prism using
a sigmoidal dose-response fit (variable slope) to determine 50%effective concentration [EC50]. Data from groups were also averaged
(n = 10) and plotted.
RFFIT neutralization assays
Serumwas first heat inactivated at 56C for 30 m. Mouse sera from days 0, 7, 14, 21, 28, 35, 56 and at necropsy (surviving mice only)
were analyzed individually in duplicate, except mock infected sera which was pooled. Rabies virus neutralizing activity was deter-
mined using the rapid fluorescent focus inhibition test assay (RFFIT) (Wunner and Jackson, 2010). Mouse neuroblastoma (NA) cells
were seeded in 96-well plates 2 days prior to the assay (30,000 cells per well). Serum samples were 2-fold serially diluted in duplicate
in 96-well plates, starting from at a dilution of 1:50 (unless otherwise noted) in 50 mL Opti-MEM (Life Technologies). The U.S. standard
rabies immune globulin was used at 2 IU/ml. Working dilutions of RABV strain CVS-11 were prepared in Opti-MEM, and 5 mL the
working dilution was added to each well containing diluted serum. Plates were incubated for 1 h at 34C. Medium was removed
from NA cells and diluted serum/virus mixtures were transferred to the cell plates. After 2 h incubation at 34C, media was aspirated,
replacedwith freshOpti-MEM, and plates were incubated for 22 h at 34Cwith 5%CO2. Plates were then fixedwith 80%acetone and
stained with FITC-conjugated anti-RABV N antibody. 50% endpoint titers were calculated using the Reed-Muench method and con-
verted to international units (IU) per milliliter by comparing to the standard.
Generation of MOKV G PTVs
MOKVGpseudotype viruses (MOKVGPTVs) are single-round infectious particles comprised ofMOKVGs on the surface of the virion
and a VSV genome lacking G and containing Nanoluciferase and EGFP (VSVDG-NanoLuc-EGFP) packaged within the virion (Fig-
ure S7). To generate MOKV G PTVs, the human lung cell line BEAS-2B was first transfected with an expression vector containing
human codon-optimized MOKV G (pCAGGS-coMOKVG) using X-tremeGENE 9 transfection reagent (Millipore Sigma). Two days
post-transfection, cells were infected at anMOI of 1with VSVDG-NanoLuc-EGFP pseudotypedwith an irrelevant glycoprotein (Lassa
fever virus glycoprotein complex) for initial infection (Abreu-Mota et al., 2018). Two h post-infection, the inoculum was removed and
cells were washed 3 times with PBS before media was replaced. Two days post-infection, cells were inspected for GFP expression
under a fluorescent microscope and supernatant containing MOKV G PTVs was collected. MOKV G PTVs were passaged 3 times
prior to use in the neutralization assay to ensure a pure population of virions.




Pseudotype virus neutralization assay
Serum was first heat inactivated at 56C for 30 m. Individual mouse sera were analyzed in triplicate. Serum was diluted 10-fold start-
ing at 1:100 dilution in Opti-MEM (Life Technologies) and 104 MOKV G PTV particles were added to each dilution. The mix of sera/
antibody plus virus was incubated for 1 h at 34C with 5% CO2 and transferred to a previously seeded monolayer of VERO cells in a
96-well plate and further incubated for 2 h at 34Cwith 5%CO2. Next, the virus/serummixwas replacedwith DMEM. At 18–22 h post-
infection, media was removed and cells were lysedwith 40 mL 1X cell culture lysis buffer (Promega) and transferred to awhite, opaque
96-well plate. The Nano-Glo Luciferase Assay System (Promega) was then used according to the manufacturer’s recommendations.
Relative luminescence units (RLU) were normalized to 100% infectivity signal as measured by no sera control (maximum signal) and
signal from naive samples were background subtracted from experimental samples. Values that were above 100% infectivity were
converted to 100%. Half maximal inhibition (IC50) values were calculated by GraphPad Prism 7 using a nonlinear fit model (Log (in-
hibitor) versus normalized response — variable slope). IC50 data analyzed for statistical significance by the Mann-Whitney test.
Microneutralization assay
Sera from vaccinatedmice were tested for VNAs against wild-type lyssaviruses using amicro-neutralization test (Kuzmin et al., 2008;
Smith and Gilbert, 2017). Briefly, serum was heat inactivated at 56C for 30 m, diluted 5-fold starting at 1:10 dilution in MEM supple-
mented with 10% FBS (CDC Division of Scientific Resources or Atlanta Biologics), and incubated at 37C for 90 m with 50 FFD50 of
each of the following non-RABV lyssaviruses: RABV (CVS-11 strain), Irkut virus (IRKV), European bat lyssavirus 1 (EBLV1) Duvenhage
virus (DUVV), Lagos bat virus (LBV, lineage B and lineage D), Shimoni bat virus (SHIBV), Mokola virus (MOKV). Individual mouse sera
were analyzed in duplicate. Assays were performed either on 6mm Teflon-coated slides or in 96-well cell culture plates. After incu-
bation ~50,000 cells/ml BSR (a clone of BHK-21) cells were added and mixtures were incubated at 37C, 0.5% CO2 for 20 to 44 h
(depending on the virus used). Cells were then fixed with cold acetone and stained with FITC-conjugated anti-RABV N antibody
(Fujirebio). Tenmicroscopic fieldswere observed for each dilution under fluorescentmicroscopy and 50%endpoint titers were calcu-
lated using the Reed-Muench method. Titers from pooled, naive (day 0) sera from each group were background subtracted from im-
mune serum titers. Titers > 1:10 were considered positive for VNAs. Micro-neutralization tests for LBV, MOKV, and SHIBV were per-
formed under biosafety level 3 (BL3) conditions. The other tests were performed under BL2 conditions.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analysis was performed using GraphPad Prism software (version 8). ELISA EC50 values were compared by Kruskal-
Wallis tests and Dunn’s multiple comparisons tests. RABV VNA titers were compared by two-way ANOVA and Tukey’s multiple
comparisons tests. MOKV pseudotype IC50 values were compared using the Mann-Whitney test. Survival was analyzed using the
log-rankMantel-Cox test. Microneutralization data were analyzed using an ordinary one-way ANOVA test with Tukey’s multiple com-
parisons. Where applicable, data was analyzed in a D’Agostino-Pearson omnibus normality test to check for normal distribution.
Additional details of data processing are detailed in respective methods descriptions and additional details of statistical tests can
be found in the figure legends.
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